Thymoma: Radiation and Chemotherapy

Koh, Wui-Jin; LoehrerSr., Patrick J.; ThomasJr., Charles R.

doi:10.1007/978-3-642-79426-1_3

Cited by 11 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thymic carcinoma is much less common than thymomas and usually presents in patients with more advanced disease. For patients with localized thymoma or thymic carcinoma, surgery and/or radiotherapy usually is the treatment of choice 19. More recently, several prospective trials have demonstrated chemosensitivity for thymoma and, to a lesser degree, thymic carcinoma.…”

Section: Discussionmentioning

confidence: 99%

Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma

Loehrer

Jiroutek

Aisner

et al. 2001

Cancer

Self Cite

172

View full text Add to dashboard Cite

BACKGROUND Patients with thymic tumors (thymoma and thymic carcinoma) are known to respond to a variety of chemotherapeutic agents, including single‐agent ifosfamide and cisplatin with etoposide. The purpose of this trial was to evaluate the response rate, progression free survival, overall survival, and toxicity of combined etoposide, ifosfamide, and cisplatin (VIP) in patients with advanced thymoma and thymic carcinoma. METHODS From July 1995 through February 1997, 34 patients with advanced thymoma or thymic carcinoma were entered on trial to receive etoposide (75 mg/m2 on Days 1–4) ifosfamide (1.2 g/m2 on Days 1–4), and cisplatin (20 mg/m2 on Days 1–4). Cycles were repeated every 3 weeks for four total cycles. RESULTS Among 28 evaluable patients (pathology review excluded 6 patients), there were no complete responses and 9 partial responses (complete and partial responses combined, 32%; 95% confidence interval, 16–52%). The median follow‐up was 43 months (range, 12.8–52.3 months), the median duration of response was 11.9 months (range, < 1–26 months), and the median overall survival was 31.6 months. Based on Kaplan–Meier estimates, the 1‐year and 2‐year survival rates were 89% and 70%, respectively. The toxicity was predominantly myelosuppression. CONCLUSIONS The VIP regimen has moderate activity in patients with advanced thymic malignancies. However, with limited follow‐up, the results of this trial appear to be inferior to other chemotherapy regimens reported in large Phase II trials performed in patients with this disease. Cancer 2001;91:2010–5. © 2001 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma

Loehrer

Jiroutek

Aisner

et al. 2001

Cancer

Self Cite

172

View full text Add to dashboard Cite

show abstract

“…For patients with localized thymoma or thymic carcinoma, surgery and/or radiotherapy usually is the treatment of choice. 19 More recently, several prospective trials have demonstrated chemosensitivity for thymoma and, to a lesser degree, thymic carcinoma. To date, the most commonly reported combination chemotherapeutic regimens for thymomas contain both cisplatin and doxorubicin.…”

Section: Discussionmentioning

confidence: 99%

Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma

Loehrer¹,

Jiroutek²,

Aisner³

et al. 2001

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…There are various postoperative dose and fraction schemes reported in the literature [123], but generally 45-55 Gy are recommended [8,11,13,88,[124][125][126][127], even if there is no clear dose-response relationship because of the relatively small number of patients enrolled in the different studies and lack of prospective randomised trials. In patients with bulky disease, doses higher than 60 Gy have been proposed [127,128] since lower doses have been found to adversely affect prognosis [129].…”

Section: Radiotherapymentioning

confidence: 99%

Thymoma and thymic carcinoma

Venuta

Anile

Diso

et al. 2010

European Journal of Cardio-Thoracic Surgery

183

152

View full text Add to dashboard Cite

Thymoma and thymic carcinoma are an extremely heterogeneous group of neoplastic lesions with an exceedingly wide spectrum of morphologic appearances. They show different presentations with a variable and unpredictable evolution ranging from an indolent non-invasive attitude to a highly infiltrative and metastasising one. Prognosis can be predicted on the basis of a number of variables, mainly staging, the WHO histological pattern and diameter of the tumour. Complete surgical resection is certainly the gold standard to achieve cure. However, especially in patients with lesions at advanced stage, complete resection may be difficult and recurrence often occurs; at these stages, disease-free long-term survival may be difficult to be accomplished. Chemo- and radiotherapy protocols have been designed to complete surgical treatment and improve results in inoperable patients as well, based on the reported sensitivity of thymic tumours to these treatment modalities. The integration of clinical staging and histology, with the new histogenetic morphological classification, has contributed to design multimodality treatment protocols that help to improve prognosis. Induction therapy can now be applied before surgery in patients with tumours considered inoperable, improving resectability and outcome without adding morbidity and mortality to the surgical procedure. This newly developed approach helps to reduce the recurrence rate and to ameliorate disease-free survival. New therapies are now being evaluated as for many other tumours; however, they still need confirmation in prospective randomised studies. In the future, integrated treatment modality should be incorporated in a standardised approach that goes from a careful assessment of histology, staging and lymph node status, and a constructive and non-empirical co-operation between medical and radiation oncologists, pathologists and thoracic surgeons.

show abstract

Thymoma: Radiation and Chemotherapy

Cited by 11 publications

References 42 publications

Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma

Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma

Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma

Thymoma and thymic carcinoma

Contact Info

Product

Resources

About